Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Galectin Therapeutics Inc. is a biotechnology company focused on developing therapies for fibrotic diseases and cancer, particularly leveraging its proprietary galectin technology platform. The company's lead product candidate, GR-MD-02, is in clinical trials for non-alcoholic steatohepatitis (NASH) and other fibrotic conditions, positioning it uniquely in the therapeutic landscape.
Currently, Galectin Therapeutics does not generate revenue but aims to monetize its galectin-based therapies through partnerships and eventual product sales. The company has a competitive advantage in its unique approach to targeting galectin proteins, which are implicated in various diseases, potentially leading to high pricing power if its products are successful.
Clinical trial results for GR-MD-02 in NASH and other indications
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA or other agencies
Market sentiment regarding the biotechnology sector
Regulatory changes affecting drug approval processes
Technological disruption in biotechnology research methodologies
Emergence of alternative therapies for NASH and fibrosis
Increased competition from larger biotech firms with more resources
Liquidity risk due to negative cash flows and reliance on external funding
Potential for dilution if additional equity financing is required
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending is often prioritized.
Moderate - Rising interest rates could increase the cost of capital for financing clinical trials, but the company is not currently reliant on debt financing.
minimal - The company has a negative debt/equity ratio, indicating it does not have significant credit exposure.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has shown significant volatility, evidenced by a 136.5% return over the past year.
